A Flechon

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. request reprint
    Flechon A, Biron P, Droz J. High-dose chemotherapy with hematopoietic stem-cell support in germ-cell tumor patient treatment: the French experience. Int J Cancer. 1999;83:844-7 pubmed
    ..A European randomized trial, which studies the role of HDCT in the first-line salvage treatment of non-refractory disease, is ongoing. So far, HDCT is not a standard treatment of GCT. ..
  2. Flechon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G, et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 t. Ann Oncol. 2011;22:2476-81 pubmed publisher
    ..The median follow-up was 9.3 months [95% confidence interval (CI) 0.2-27.1] and the median overall survival 9.6 months (95% CI 8.7-12.7). The benefit-risk ratio of this regimen seems unfavorable due to poor response and high toxicity. ..
  3. Flechon A, Tavernier E, Boyle H, Meeus P, Rivoire M, Droz J. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour. BJU Int. 2010;106:779-85 pubmed publisher
    ....

Locale

Detail Information

Publications3

  1. request reprint
    Flechon A, Biron P, Droz J. High-dose chemotherapy with hematopoietic stem-cell support in germ-cell tumor patient treatment: the French experience. Int J Cancer. 1999;83:844-7 pubmed
    ..A European randomized trial, which studies the role of HDCT in the first-line salvage treatment of non-refractory disease, is ongoing. So far, HDCT is not a standard treatment of GCT. ..
  2. Flechon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G, et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 t. Ann Oncol. 2011;22:2476-81 pubmed publisher
    ..The median follow-up was 9.3 months [95% confidence interval (CI) 0.2-27.1] and the median overall survival 9.6 months (95% CI 8.7-12.7). The benefit-risk ratio of this regimen seems unfavorable due to poor response and high toxicity. ..
  3. Flechon A, Tavernier E, Boyle H, Meeus P, Rivoire M, Droz J. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour. BJU Int. 2010;106:779-85 pubmed publisher
    ....